IRAK4-IN-14

IRAK4-IN-14 (compound 28) is a potent, selective and orally active IRAK4 inhibitor with an IC50 of 0.003 μM. IRAK4-IN-14 shows good PK parameters in rats and mouse. IRAK4-IN-14 shows synergistic in vitro activity against MyD88/CD79 double mutant ABC-DLBCL in combination with Acalabrutinib[1].

Product Specifications

CAS Number

[2667681-71-0]

UNSPSC

12352005

Target

IRAK

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/irak4-in-14.html

Purity

99.01

Solubility

DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

CC1=NC=C(C2=NC3=C(OC4(C)CC4)N=C(NC5=CN(C6CCN(C)CC6)N=C5)N=C3C=C2F)C=N1

Molecular Formula

C25H28FN9O

Molecular Weight

489.55

References & Citations

[1]Degorce SL, et al. Improving metabolic stability and removing aldehyde oxidase liability in a 5-azaquinazoline series of IRAK4 inhibitors. Bioorg Med Chem. 2020 Dec 1;28 (23) :115815.